BioScrip Will Expand PBM Business Following Chronimed/MIM Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharmacy companies will build upon MIM’s $400 mil. PBM business (ScripSolutions) ahead of the Medicare drug benefit implementation in 2006. Chronimed CEO Blissenbach, who has executive experience from the PBM industry, will become BioScrip CEO following the close of the deal.
You may also be interested in...
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.
Pfizer In Talks With FDA Over Viagra Label Update To Reflect Vision Loss
Discussions follow an FDA investigation prompted by journal article reporting 15 cases of non-arteritic anterior ischemic optic neuropathy in sildenafil patients. Pfizer said a review of 103 clinical trials found no reports of the NAION; the company has submitted 23 cases to FDA since Viagra entered the market in 1998.